Top Back to top

Autologous Stem Cell Transplantation International Crohn's Disease Trial: a multicentre, prospective, randomised phase II study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation

Study number:
2005-003337-40
Type of transplant:
 
Short title:
ASTIC
Study status:
Follow-up
Deadline for data collection:
 
Study design:
Open label, randomised multicentre study
Primary objective:
To evaluate the potential clinical benefit of hematopietic stem cell mobilisation by high dose immunoablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice in patients with Crohn's disease
Key inclusion criteria:
18-50 years old
Country:
United Kingdom
France
Czech Republic
Germany
Italy
Spain
Switzerland
Canada
Principal investigator:
Christopher J Hawkey
Principal investigator email:
 
EBMT Study coordinator:
Janette Zarev

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org